Escoín, C. (Corina)

Filtering

20191

Settings

Author search.filters.isAuthorOfPublication.26416451-d742-4dac-bd83-ce01c0f7954d

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
    (2019) Muñarriz, J. (Javier); Chirivella, I. (Isabel); Climent, M.A. (Miguel Ángel); Basterretxea, L. (Laura); Reynés, G. (Gaspar); Esteban-Gutiérrez, E. (Emilio); Cassinello, J. (Javier); Vázquez, S. (Sergio); Juan-Fita, M. J. (María José); Escoín, C. (Corina); de Ávila-Lizárraga, L. (Leticia); Sánchez-Lorenzo, M. L. (María Luisa); Puente, J. (Javier)
    Purpose: The aim of this multicenter study was to evaluate the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib retreatment. Methods: Clinical data from patients treated with sunitinib rechallenge in nine Spanish centers were retrospectively analyzed. All patients received first-line sunitinib until progression or intolerance, followed by one or more successive drugs and rechallenge with sunitinib thereafter. Results: Thirty-seven patients were included. At first-line treatment, objective response rate (ORR) was 69.4% and median progression-free survival (PFS) was 19.4 months. At rechallenge, ORR was 27.2% and 39.4% of patients obtained stabilization of disease. Median PFS was 6.2 months. Clinical benefit was obtained by 21 patients (75%) with > 6-month interval between sunitinib treatments and by 1 patient (20%) among those with ≤ 6-month interval (P = 0.016). Hemoglobin levels ≥ lower level of normal were associated with clinical benefit (P = 0.019) and with PFS (P = 0.004). Median overall survival from start of first-line sunitinib was 52.7 months. No new adverse events were observed at rechallenge. Conclusions: Sunitinib rechallenge is a feasible treatment option for selected patients with mRCC.